A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Helen M. Colhoun, D. J. Betteridge, Paul N. Durrington et al. · The Lancet · 2004 · 3.8K citations

Medicine, Pharmacotherapy, Preventive Medicine +9

Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events

Paul M. Ridker, Nader Rifai, Lynda Rose et al. · New England Journal of Medicine · 2002 · 3.6K citations · Full text

Medicine, Gynecology, High-risk Pregnancy +3

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

Paul M. Ridker, Francisco Antônio Helfenstein Fonseca, Jacques Genest et al. · The Lancet · 2009 · 1K citations

Medicine, Pharmacology, Pharmacotherapy +17

Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis

Stephen J. Nicholls, E. Murat Tuzcu, İlke Sipahi et al. · JAMA · 2007 · 730 citations

Medicine, Cardiology, Cardiovascular Pharmacotherapy +13

Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes

Peter Sever, Neil R Poulter, Björn Dahlöf et al. · Diabetes Care · 2005 · 394 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17